Nerve damage is a recognised side effect of some CAR-T therapies for cancer, and one that could be spotted early using a pen device developed by UK company Manus Neurodyna
AstraZeneca has extended a contract to use a digital health device developed by ImpediMed that is being deployed in a trial of two of its drugs in chronic kidney disease (CKD).
Medtech giant Beckton Dickinson (BD) has signed a deal with France's Biocorp to use the latter's near-field communication (NFC) tags in injectable devices.